Evidence map›Paper›PMID 37162982›Full record

ArticlebioRxiv : the preprint server for biology2023

BEERS2: RNA-Seq simulation through high fidelity

Thomas G Brooks, Nicholas F Lahens, Antonijo Mrčela, Dimitra Sarantopoulou, Soumyashant Nayak, Amruta Naik, Shaon Sengupta, Peter S Choi, Gregory R Grant

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Thomas G BrooksInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Nicholas F LahensInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Antonijo MrčelaInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Dimitra SarantopoulouInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Soumyashant NayakInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Amruta NaikInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Shaon SenguptaInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Peter S ChoiDivision of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Gregory R GrantInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, PA, USA.
Translational Therapeutics (United States) · USChildren's Hospital of Philadelphia · USNational Institutes of Health · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Mechanistic evaluation of the role of circadian rhythms in acute lung injury and subsequent recoveryR01HL155934 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI SENGUPTA, SHAON · 2021 to 2025
$2.9M
Exploring hidden determinants of splicing with genome-targeted proximity labelingDP2GM146251 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI CHOI, PETER S. · 2021 to 2024
$2.7M
Regulation of neonatal inflammation by myeloid-derived suppressor cellsR01HL147472 · NHLBI · WISTAR INSTITUTE · PI NEFEDOVA, YULIA · 2020 to 2023
$2.5M
The next generation of RNA-Seq simulators for benchmarking analysesR21LM012763 · NLM · UNIVERSITY OF PENNSYLVANIA · PI GRANT, GREGORY R · 2018 to 2019
$398k
NCATS NIH HHS UL1 TR000003NHLBI NIH HHS R01 HL147472NHLBI NIH HHS R01 HL155934NIGMS NIH HHS DP2 GM146251NLM NIH HHS R21 LM012763
6 · The paper itself

Abstract

Simulation of RNA-seq reads is critical in the assessment, comparison, benchmarking, and development of bioinformatics tools. Yet the field of RNA-seq simulators has progressed little in the last decade. To address this need we have developed BEERS2, which combines a flexible and highly configurable design with detailed simulation of the entire library preparation and sequencing pipeline. BEERS2 takes input transcripts (typically fully-length mRNA transcripts with polyA tails) from either customizable input or from CAMPAREE simulated RNA samples. It produces realistic reads of these transcripts as FASTQ, SAM, or BAM formats with the SAM or BAM formats containing the true alignment to the reference genome. It also produces true transcript-level quantification values. BEERS2 combines a flexible and highly configurable design with detailed simulation of the entire library preparation and sequencing pipeline and is designed to include the effects of polyA selection and RiboZero for ribosomal depletion, hexamer priming sequence biases, GC-content biases in PCR amplification, barcode read errors, and errors during PCR amplification. These characteristics combine to make BEERS2 the most complete simulation of RNA-seq to date. Finally, we demonstrate the use of BEERS2 by measuring the effect of several settings on the popular Salmon pseudoalignment algorithm.

Identifiers

PMID37162982
PMCPMC10168222
OpenAlexW4366815094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.